KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $23,987.88 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,394 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $10.02, for a total value of $23,987.88. Following the transaction, the insider now directly owns 102,940 shares of the company’s stock, valued at approximately $1,031,458.80. This trade represents a 2.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

KalVista Pharmaceuticals Stock Up 1.0 %

Shares of KalVista Pharmaceuticals stock opened at $10.88 on Thursday. The business has a 50-day moving average price of $8.98 and a 200 day moving average price of $10.35. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The firm has a market cap of $537.77 million, a P/E ratio of -2.99 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Aquatic Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $44,000. Tower Research Capital LLC TRC raised its stake in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 5,502 shares in the last quarter. Legal & General Group Plc boosted its position in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares during the period. Martin Worley Group bought a new position in shares of KalVista Pharmaceuticals in the fourth quarter worth $86,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after purchasing an additional 2,043 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on KALV. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company. JMP Securities started coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).